SG Americas Securities LLC Makes New $117,000 Investment in Pulmonx Co. (NASDAQ:LUNG)

SG Americas Securities LLC purchased a new position in shares of Pulmonx Co. (NASDAQ:LUNG) in the fourth quarter, Holdings Channel reports. The fund purchased 9,184 shares of the company’s stock, valued at approximately $117,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Point72 Asset Management L.P. boosted its position in Pulmonx by 7.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 3,326,065 shares of the company’s stock worth $43,605,000 after acquiring an additional 242,815 shares during the period. Vanguard Group Inc. boosted its position in Pulmonx by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,151,742 shares of the company’s stock worth $52,509,000 after acquiring an additional 18,232 shares during the period. Capital World Investors boosted its position in Pulmonx by 7.0% during the 1st quarter. Capital World Investors now owns 2,946,500 shares of the company’s stock worth $73,103,000 after acquiring an additional 192,000 shares during the period. BlackRock Inc. boosted its position in Pulmonx by 7.6% during the 2nd quarter. BlackRock Inc. now owns 2,911,766 shares of the company’s stock worth $38,173,000 after acquiring an additional 205,821 shares during the period. Finally, Morgan Stanley boosted its position in Pulmonx by 12.5% during the 3rd quarter. Morgan Stanley now owns 2,219,826 shares of the company’s stock worth $22,931,000 after acquiring an additional 246,302 shares during the period. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Trading Up 0.9 %

Shares of NASDAQ LUNG opened at $7.50 on Friday. Pulmonx Co. has a 12 month low of $7.21 and a 12 month high of $14.84. The company has a market cap of $289.05 million, a price-to-earnings ratio of -4.69 and a beta of 0.60. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30. The business has a fifty day simple moving average of $9.90 and a 200-day simple moving average of $10.81.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, February 21st. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.02. The business had revenue of $19.30 million during the quarter, compared to the consensus estimate of $18.24 million. Pulmonx had a negative return on equity of 46.63% and a negative net margin of 88.60%. Pulmonx’s revenue was up 25.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.38) earnings per share. Sell-side analysts predict that Pulmonx Co. will post -1.79 EPS for the current year.

Insider Activity at Pulmonx

In related news, insider Geoffrey Beran Rose sold 3,097 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $9.06, for a total transaction of $28,058.82. Following the transaction, the insider now directly owns 239,952 shares of the company’s stock, valued at $2,173,965.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Geoffrey Beran Rose sold 3,097 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $9.06, for a total transaction of $28,058.82. Following the transaction, the insider now directly owns 239,952 shares of the company’s stock, valued at $2,173,965.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Glendon E. French III sold 20,000 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.60, for a total value of $292,000.00. Following the transaction, the chief executive officer now directly owns 1,121,344 shares in the company, valued at $16,371,622.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,032 shares of company stock valued at $475,690. Company insiders own 5.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Stifel Nicolaus upped their price objective on Pulmonx from $15.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Citigroup upped their price objective on Pulmonx from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Piper Sandler restated an “overweight” rating and issued a $17.00 price objective on shares of Pulmonx in a report on Wednesday, April 3rd. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $14.00 price objective (down previously from $16.00) on shares of Pulmonx in a report on Friday, February 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.83.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.